AbbVie Opens Biomanufacturing Plant in SingaporeBy
AbbVie has opened a new biologics manufacturing facility in Tuas Biomedical Park, Singapore as part of a previously announced $320-million expansion for both small molecule and biologics drug-substance manufacturing. The plant is a mammalian cell-culture drug substance manufacturing facility equipped with both stainless and single-use equipment.
In 2014, AbbVie announced the $320-million investment to establish operations in Singapore for small-molecule and biologics active drug-substance manufacturing. The 120,000-square-meter site is the company’s first manufacturing site in Asia. The small-molecule manufacturing facility opened in September 2016, and the biologics manufacturing facility is expected to be fully operation by 2019. The new biologics facility will provide manufacturing capacity for emerging compounds within AbbVie’s oncology and immunology pipeline to serve markets globally. When fully operational, the facility is expected to employ more than 250 people.
AbbVie now has 14 manufacturing sites: US (North Chicago and Abbott Park, Illinois; Worcester, Massachusetts; Wyandotte, Michigan; Puerto Rico (two in Barceloneta; one in Jayuya); Italy; Germany; Ireland (two in Sligo; one in Cork); and Singapore (two).